Welcome to our dedicated page for OTIC news (Ticker: OTIC), a resource for investors and traders seeking the latest updates and insights on OTIC stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect OTIC's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of OTIC's position in the market.
Otonomy, Inc. (Nasdaq: OTIC) announced participation in the 20th Annual Needham Virtual Healthcare Conference. David A. Weber, Ph.D., the company's president and CEO, will present an overview on April 13, 2021, at 4:30 p.m. ET. A live audio webcast can be accessed on Otonomy's website, with an archive available post-event.
The company focuses on developing innovative therapeutics for neurotology, utilizing drug delivery technology to create sustained drug exposure from a single local administration, specifically targeting hearing loss and tinnitus.
Otonomy, Inc. (Nasdaq: OTIC) has announced the upcoming presentation of clinical results from its OTO-313 Phase 1/2 trial at the COSM conference, scheduled for April 10, 2021. Kenneth Maxwell, M.D., will present the findings, highlighting a significant step forward in addressing tinnitus, a condition currently lacking approved drug treatments. The Phase 2 trial has recently been initiated to further build on these promising results. Otonomy focuses on innovative therapeutics for neurotology, emphasizing sustained drug delivery to treat hearing loss and tinnitus.
Otonomy has announced the initiation of a Phase 2 clinical trial for OTO-313, targeting patients with unilateral tinnitus. This study follows a successful Phase 1/2 trial and aims to enroll approximately 140 patients. The primary efficacy endpoint is a responder analysis based on Tinnitus Functional Index scores, with top-line results expected by mid-2022. Tinnitus affects an estimated 10% of U.S. adults, highlighting an unmet medical need, as there are currently no approved drug treatments for this condition.
Otonomy, Inc. (Nasdaq: OTIC) announced participation in three virtual conferences: a fireside chat at the Cowen 41st Annual Health Care Conference on March 4, 2021, at 12:50 p.m. ET, a pre-recorded presentation at the H.C. Wainwright Global Life Sciences Conference available on-demand starting March 9, 2021, and a presentation at the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021, at 11:20 a.m. ET. Live audio webcasts will be accessible through the company's website.
Otonomy focuses on innovative therapeutics for neurotology, addressing conditions like Ménière’s disease and tinnitus.
Otonomy, Inc. (OTIC) announced that its Phase 3 clinical trial for OTIVIDEX in Ménière’s disease failed to meet the primary endpoint, showing no significant difference in definitive vertigo days compared to placebo (p=0.312). However, the per protocol analysis did yield significant results (p=0.031). CEO David A. Weber expressed disappointment but emphasized the company's strong pipeline, including promising results from OTO-313 and OTO-413, which target unmet medical needs in tinnitus and hearing loss. Otonomy reported cash reserves of $86.3 million, sufficient to support upcoming clinical readouts.
Otonomy, Inc. (Nasdaq: OTIC) announced positive top-line clinical results for OTO-313 in tinnitus and OTO-413 in hearing loss at the ARO 44th Annual MidWinter Meeting. The company will present supportive preclinical data for OTO-825 gene therapy and OTO-510 otoprotection program. The presentations highlight Otonomy's commitment to innovative therapeutics in neurotology, with significant contributions from their research team. The event takes place virtually from February 20-24, 2021, showcasing advancements in treatments for hearing-related conditions.
Otonomy, Inc. (Nasdaq: OTIC) reported its financial results for Q4 and the year ending December 31, 2020, revealing progress in its product pipeline. Key highlights include the completion of the OTIVIDEX Phase 3 trial for Ménière’s disease, with results expected by February's end. The company also plans to initiate the OTO-313 Phase 2 trial in tinnitus in Q1 2021 and expand the OTO-413 Phase 1/2 trial in hearing loss by Q2 2021. Financially, Otonomy had $86.3 million in cash as of December 31, 2020, and reduced operating expenses year-over-year.
Otonomy, Inc. (Nasdaq: OTIC) announced it will report its financial results for Q4 and the full year 2020 on February 11, 2021, at 4:30 p.m. ET. The company focuses on developing innovative therapeutics for neurotology, utilizing advanced drug delivery technology for sustained drug exposure. This technology addresses unmet medical needs such as Ménière’s disease, hearing loss, and tinnitus. Interested parties can access the live call by phone or via a webcast on the company's investor relations website.
Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical firm focused on innovative therapeutics for neurotology, announced management's participation in a fireside chat at the virtual H.C. Wainwright BioConnect 2021 Conference from January 11-14, 2021. The chat will be accessible on-demand starting January 11 at 6 a.m. EST via the H.C. Wainwright conference portal, and an archived version will be available on the company's Events page. Otonomy specializes in drug delivery technology for ear-related conditions, addressing issues like Ménière’s disease, hearing loss, and tinnitus.
Otonomy announced positive results from the Phase 1/2 trial of OTO-413, aimed at improving speech-in-noise hearing difficulties. A single intratympanic injection showed 67% of participants demonstrated significant improvement compared to no improvement in the placebo group. The treatment was well-tolerated, with no serious adverse events reported. Otonomy plans to continue developing OTO-413, building on this trial's success to address the needs of individuals with hearing loss.
